Cerebrolysin vs Trofinetide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: FPE 1070
Cerebrolysin is not a single peptide but a mixture: a preparation of small peptides and free amino acids made by enzymatically breaking down purified porcine (pig) brain protein, manufactured by EVER Neuro Pharma in Austria. It is given by injection and is approved as a prescription drug in dozens of countries for stroke, traumatic brain injury, and dementia, but it is not FDA-approved in the United States. Despite decades of use abroad, the human evidence remains genuinely contested.
Also: Daybue, Daybue Stix
Trofinetide is a synthetic version of a tiny three-amino-acid fragment (glycine-proline-glutamate) that the body clips off IGF-1. It is the first drug ever approved for Rett syndrome: the FDA approved it as Daybue in March 2023 for patients 2 years and older, Health Canada followed in October 2024, and the EU authorised it as Daybu in August 2026 after first refusing it. It is a real, approved medicine with a real but modest effect, and the trade-off is blunt: most patients get diarrhea, and a meaningful share stop because of it.
Key Comparison Insights
- Trofinetide is FDA approved, while Cerebrolysin remains in research stages.
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- Trofinetide has stronger research evidence (FDA Approved) compared to Cerebrolysin (Human Trials).
Detailed Comparison
| Attribute | Cerebrolysin | Trofinetide |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The proposed idea is that Cerebrolysin's small peptides act like the body's own neurotrophic factors, the molecules such as BDNF and NGF that help neurons survive, grow, and form connections. Researchers hypothesize it engages neurotrophic signaling pathways and may protect neurons from injury and support repair after stroke or brain trauma. It is important to be clear that the exact active components and mechanism are not fully defined, partly because it is a complex biological mixture rather than one purified molecule. So the neurotrophic-mimic story is a plausible hypothesis supported by some lab data, not a precisely mapped pathway. | Rett syndrome is usually caused by loss-of-function mutations in the MECP2 gene, which disrupts how neurons mature and connect. Trofinetide is an analog of GPE, the N-terminal tripeptide of IGF-1, built to survive longer in the body than the natural fragment. In Mecp2-deficient mice, GPE partially reversed Rett-like symptoms, and the working theory is that trofinetide supports synaptic function and dampens neuroinflammation. The honest part: the FDA label states that the mechanism by which trofinetide works in Rett syndrome is unknown. It is taken by mouth in large gram-level doses, has an elimination half-life of about 1.5 hours, and is cleared mainly by the kidneys, which is why it is not recommended in moderate or severe kidney impairment. |
| Common Dosing | 20-32 mg/day (a 60mg vial reconstituted in 3 mL bacteriostatic water gives 20 mg/mL) Once or twice daily, with amounts above 20 mg divided between morning and evening, escalated gradually | 5-12 g twice daily, set by body weight (labeled dose) Twice daily, morning and evening |
| Administration | Subcutaneous (research) or intravenous/intramuscular (clinical literature) | Oral solution (200 mg/mL) by mouth or via gastrostomy tube; also available as a powder (Daybue Stix) mixed into liquid |
| Typical Duration | 8-16 week protocols for research-scale subQ; 10-20 day cycles for clinical IV | Ongoing for the approved indication; dose is interrupted, reduced, or stopped for severe diarrhea, dehydration, or significant weight loss |
| Best Time to Take | Morning | Morning and evening, as prescribed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Cerebrolysin has been tested in many human trials, but the quality and consistency of that evidence is the real story. A Cochrane systematic review on vascular dementia (Cui and colleagues, 2019) concluded that intravenous Cerebrolysin may improve cognition and global function, but cautioned the findings were not definitive because of high risk of bias and heterogeneity across studies. Cochrane reviews of acute ischemic stroke have similarly found insufficient or inconclusive evidence and have flagged a possible signal of increased non-fatal serious adverse events in some analyses. The Alzheimer's Drug Discovery Foundation's Cognitive Vitality review rates the human evidence as mixed and far from conclusive. So while it is a real, widely prescribed drug in many countries, the claim that it reliably improves brain outcomes is not established to Western regulatory standards, and many of the supporting trials come from a narrow set of investigators and sponsors. | Approval rests on one pivotal trial, LAVENDER (Neul and colleagues, Nature Medicine 2023): 187 girls and young women aged 5 to 20 with Rett syndrome, randomized to trofinetide or placebo for 12 weeks. Both co-primary endpoints were hit. The caregiver-rated Rett Syndrome Behaviour Questionnaire improved by 4.9 points versus 1.7 on placebo, and the clinician-rated CGI-I score was 3.5 versus 3.8, with effect sizes in the small-to-moderate range (Cohen's d 0.37 and 0.47). A communication measure also favored the drug. The price was tolerability: diarrhea hit about 81% on trofinetide versus 19% on placebo, vomiting 27% versus 10%, and 17% dropped out for side effects (mostly diarrhea). The label adds that 12% lost more than 7% of body weight. Open-label extensions (LILAC and the 32-month LILAC-2, published in Med in 2024) reported continued improvement, but without a placebo arm those data cannot prove the drug caused it. In December 2025 the FDA approved Daybue Stix, a powder version, based on a bioequivalence study. In Europe, the EMA's committee first refused the application in February 2026, then recommended approval on re-examination in June 2026 for patients 5 and older, noting the improvements were small but relevant for a serious disease and that the trial showed no effect on seizures. Bottom line: a genuine first treatment for a disease that had none, with modest benefit and a heavy GI cost. |
Frequently Asked Questions: Cerebrolysin vs Trofinetide
What is the difference between Cerebrolysin and Trofinetide?
Cerebrolysin is a cognitive peptide that cerebrolysin is not a single peptide but a mixture: a preparation of small peptides and free amino acids made by enzymatically breaking down purified porcine (pig) brain protein, manufactured by ever neuro pharma in austria. it is given by injection and is approved as a prescription drug in dozens of countries for stroke, traumatic brain injury, and dementia, but it is not fda-approved in the united states. despite decades of use abroad, the human evidence remains genuinely contested. Trofinetide is a cognitive peptide that trofinetide is a synthetic version of a tiny three-amino-acid fragment (glycine-proline-glutamate) that the body clips off igf-1. it is the first drug ever approved for rett syndrome: the fda approved it as daybue in march 2023 for patients 2 years and older, health canada followed in october 2024, and the eu authorised it as daybu in august 2026 after first refusing it. it is a real, approved medicine with a real but modest effect, and the trade-off is blunt: most patients get diarrhea, and a meaningful share stop because of it. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Cerebrolysin or Trofinetide?
Neither is universally "better" - the choice depends on your specific goals. Cerebrolysin is typically used for cognitive purposes, while Trofinetide is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Cerebrolysin and Trofinetide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Cerebrolysin and Trofinetide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.